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Abstract
Background: Visceral leishmaniasis (VL) is diagnosed by microscopic confirmation of the parasite in bone marrow, spleen or
lymph node aspirates. These procedures are unsuitable for rapid diagnosis of VL in field settings. The development of rK39-
based rapid diagnostic tests (RDT) revolutionized diagnosis of VL by offering high sensitivity and specificity in detecting
disease in the Indian subcontinent; however, these tests have been less reliable in the African subcontinent (sensitivity
range of 75–85%, specificity of 70–92%). We have addressed limitations of the rK39 with a new synthetic polyprotein, rK28,
followed by development and evaluation of two new rK28-based RDT prototype platforms.
Methodology/Principal Findings: Evaluation of 62 VL-confirmed sera from Sudan provided sensitivities of 96.8% and 93.6%
(95% CI=K28: 88.83–99.61%; K39: 84.30–98.21%) and specificities of 96.2% and 92.4% (95% CI=K28: 90.53–98.95%; K39:
85.54–96.65%) for rK28 and rK39, respectively. Of greater interest was the observation that individual VL sera with low rK39
reactivity often had much higher rK28 reactivity. This characteristic of the fusion protein was exploited in the development
of rK28 rapid tests, which may prove to be crucial in detecting VL among patients with low rK39 antibody levels. Evaluation
of two prototype lateral flow-based rK28 rapid tests on 53 VL patients in Sudan and 73 VL patients in Bangladesh provided
promisingly high sensitivities (95.9% [95% CI=88.46–99.1 in Sudan and 98.1% [95% CI=89.93–99.95%] in Bangladesh)
compared to the rK39 RDT (sensitivities of 86.3% [95% CI=76.25–93.23%] in Sudan and 88.7% [95% CI=76.97–95.73%] in
Bangladesh).
Conclusions/Significance: Our study compares the diagnostic accuracy of rK39 and rK28 in detecting active VL cases and
our findings indicate that rK28 polyprotein has great potential as a serodiagnostic tool. A new rK28-based RDT will prove to
be a valuable asset in simplifying VL disease confirmation at the point-of-care.
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Introduction
Leishmania parasites are transmitted to mammals by the bite of
female phlebotomine sand flies and occasionally by the sharing of
needles, by blood transfusion, or by congenital transmission. The
life-cycle of Leishmania has two distinct forms: the flagellated
promastigotes found in the gut of the arthropod vector and non
motile amastigotes, which develop intracellularly in the mamma-
lian host. Promastigotes injected into the skin during sand fly bite
are internalized by dendritic cells and macrophages in the dermis
where they lose their flagella as they transform into amastigotes.
They multiply and survive within the phagolysosomes through a
complex host-parasite interaction [1]. The prepatent period can
vary from weeks to months and during this period disease
symptoms may gradually appear and worsen with disease
manifestations ranging from self-healing skin lesions, to diffuse
cutaneous and mucosal manifestations and, in some cases, to
severe visceral involvement of the spleen, liver and lymph nodes
depending on the species of Leishmania.
Visceral leishmaniasis, known as kala-azar (Hindi for Black
fever) in the Indian subcontinent and Africa, is the most severe
form of the disease affecting approximately 500,000 adults and
children worldwide. Following infection, the parasites disseminate
through the lymphatic and vascular systems and infect other
monocytes and macrophages in the reticulo-endothelial system,
resulting in infiltration of the bone marrow, hepato-splenomegaly
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tality of VL is high in the absence of treatment, which is generally
lengthy, expensive and toxic. Clinical diagnosis relies on non-
characteristic symptoms (long standing fever, cachexia, anemia
and hepato-splenomegaly) which are only reliable in advanced
cases and in epidemic situations. Parasitological diagnosis remains
the reference standard in VL diagnosis, typically undertaken by
microscopic examination of Giemsa-stained bone marrow, spleen
or lymph node aspirates to detect amastigotes. This is not only
invasive, but also suffers from low sensitivity, requiring both highly
trained laboratory personnel to biopsy patients and high-powered
microscopes that are typically available only in regional clinics.
Thus, tissue aspirations for routine VL screenings are not feasible
as a large-scale approach in remote field areas lacking electricity
and even the most basic laboratory set-up.
The development of two serological tests for diagnosis of VL,
the direct agglutination test (DAT) and the rK39 strip tests, have
started to circumvent the need for tissue aspirates in Sudan and
the Indian subcontinent, respectively. DAT is the first-line VL
serodiagnostic test employed in Sudan [2] and, despite being
highly sensitive and specific [3,4], it is not optimum as a point-of-
care test as it requires a laboratory capable of holding controlled
temperature with overnight incubation. The rK39 strip test
became possible after the identification of the k39 kinesin gene
by an immunoscreen of a L. infantum expression library with sera
obtained from visceral leishmaniasis patients [5]. VL patients
mount a strong antibody response to the 39-amino acid, tandem
repeat units in the gene, and the recombinant form of this gene,
rK39, has been successfully used to develop an enzyme-linked
immunosorbent assay (ELISA) [6,7] as well as a point-of-care
RDT [8,9]. The rK39 RDT is a field-friendly, easy to use format
that has been extensively tested in many countries. In a WHO
supported multicenter trial, the FDA-approved rK39 RDT
(Kalazar Detect- Inbios, Seattle) demonstrated excellent sensitivity
(.95%) and specificity (.90%) in the Indian subcontinent (India
and Nepal), but only moderate sensitivity (75 to 85%) and
specificity (70–92%) in East Africa (Sudan, Kenya and Ethiopia)
[10]. Reasons for the suboptimal performance of the rK39 RDT
in Africa are not entirely clear and have been attributed to lower
antibody levels to rK39 in infected individuals.
We previously identified k9 and k26, two Leishmania genes
coding for hydrophilic proteins, and demonstrated that VL
patients mount strong and specific antibody responses against
K26, which can complement rK39 in a more accurate diagnosis of
human VL [11]. Specific and independent antibody reactivity to
each of the three antigens rK9, rK26 and rK39 have been studied
and utilized in serodiagnosis of canine VL [12]. A multi-epitope,
recombinant chimeric protein for serodiagnosis of canine and
human VL was evaluated by fusing L. infantum k9 gene with single
repeat units of k39 and k26 genes. ELISA with this fusion protein
provided 96% sensitivity for canine VL compared to only 82% for
human VL, with 99% specificity for both human and canine
control groups [13].
We sought to improve serodiagnosis of VL by developing
enhanced RDT prototypes that can detect .90% of the African
VL cases, thus increasing diagnostic accuracy and overcoming
limitations of the current rK39 RDT. The development of an
affordable, simple, sensitive and specific point-of-care diagnostic
test would clearly have a major impact on detection, control and
treatment of visceral leishmaniasis patients. A synthetic gene, k28,
was generated by fusing multiple tandem repeat sequences of the
L. donovani haspb1 and k39 kinesin genes to the complete open
reading frame of haspb2, thereby increasing antigen epitope
density while providing complementing epitopes in the resulting
recombinant protein. The recombinant fusion protein rK28 was
evaluated on ELISA with a panel of active human Sudanese VL
cases and also used to develop two prototype point-of-care tests,
the results of which are presented. To our knowledge, this is the
first study describing the development of a second generation
rapid test for the serodiagnosis of human VL. Our results confirm
that rK28 is an excellent serodiagnostic tool that has the potential
to replace rK39 protein pending larger field trials.
Materials and Methods
K28 gene construct
The K28 gene was synthesized at Blue Heron Biotechnology,
Bothell, WA using the Genemaker technology with a six-histidine
tag downstream of the N-terminal methionine. The synthetic gene
includes nucleotides 142–267 encompassing three 14-amino acid
(aa) repeats of (L. donovani haspb1 gene, GenBank accession#
AJ011810.1), nucleotides 2110–2343 encompassing two 39-aa
repeats of (L. donovani k39 kinesin protein gene, GenBank
accession# DQ831678.1) and nucleotides 1–400 (the complete
ORF) of L. donovani haspb2 gene, GenBank accession#
AJ011809.1). The 795 base pair (bp) product was subcloned
directionally in the Nde I/Xho I sites of pET29 (Novagen, USA),
and the transformants selected in XL-10 Gold cells (Stratagene,
Santa Clara, CA.). Following sequence verification of the insert,
the recombinant plasmid was subsequently transformed into E. coli
HMS-174(DE3) for expression of recombinant protein. The k28
gene sequence has been submitted to GenBank under accession
number HM594686.
Protein expression and purification
Recombinant K28 protein (rK28) was produced by growing the
transformed host cell HMS-174(DE3) in 2XYS with kanamycin
using a fed-batch fermentation system. The production media was
inoculated with a 10% inoculum culture in a log-growth phase.
The culture was grown in a 10 L bioreactor (New Brunswick
Scientific, Edison, NJ) to an optical density of 8–10 (A600), induced
with IPTG (1mM final concentration) for 2 hours, and the cells
Author Summary
Visceral Leishmaniasis caused by Leishmania donovani is
endemic in several parts of South Asia, East Africa, South
and Central America. It is a vector-borne disease transmit-
ted by bites of infected sand flies and often fatal in the
absence of chemotherapy. Timely diagnosis is an essential
first step in providing proper patient care and in
controlling transmission. VL diagnosis in East Africa and
Latin America are currently based on microscopic confir-
mation of parasites in tissue aspirates. The Kalazar Detect
rapid test is widely used as a confirmatory test in India with
very high accuracy, but sensitivity issues have severely
limited its usefulness in the African sub-continent. Direct
Agglutination Test is another confirmatory test used
widely in East Africa and offers high sensitivity but is not
field-friendly. We report on the design of a novel synthetic
fusion protein capable of sequestering antibodies against
three different Leishmania donovani antigens and the
development of point-of-care tests for improving VL
diagnosis. We believe the ease of use of these rapid tests
and their high accuracy in detecting VL cases could make
them useful as a first-line test, thereby eliminating the
need for painful biopsies and ensuring better patient care.
Rapid Test for Diagnosis of Visceral Leishmaniasis
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pH 8.0 using an 110S microfluidizer (Microfluidics, Newton, MA)
and cellular debris removed by centrifugation. The supernatant
containing the expressed protein was combined with Ni-NTA
agarose (QIAGEN, Valencia, CA) in a batch-bind mode and
incubated overnight at 4uC. The resin was then packed in a
column and washed with 10 column volumes of 20 mM Tris-Cl,
pH 8.0, 250 mM NaCl, 0.5% CHAPS. Bound protein was eluted
with 20 mM Tris-Cl pH 8.0 containing 400 mM imidazole. The
eluted fractions were diluted 1:3 with 20 mM Tris-Cl pH 8.0 and
loaded onto a Q sepharose fast flow column (GE Healthcare
Biosciences, Piscataway, NJ). The peaks eluted at 200 to 300 mM
NaCl were combined; ammonium sulfate was added to make the
final concentration 2 M, following which hydrophobic interaction
chromatography was performed using Octyl Sepharose 4 Fast
Flow (GE Healthcare Biosciences). Peaks eluted at low salt
concentrations were combined, dialyzed into 20 mM Tris-Cl,
pH 8.0, and sterile filtered through 0.22 mm filter. The final
protein concentration was determined using BCA assay (Pierce
Chemical, Rockford, IL). The lipopolysaccharide content of each
protein preparation was measured by a Limulus amoebocyte lysate
test (BioWhittaker, Walkersville, MD) and shown to be below 10
endotoxin units (EU)/mg of protein.
Patient sera for ELISA evaluation
Disease-positive sera from 62 VL patients were obtained from
the Gedaref state of eastern Sudan. The inclusion criteria for VL
sera samples used in this study were, (i) all patients were
parasitology positive, confirmed by microscopy of lymph node or
bone marrow aspirates, (ii) all patients had clinical symptoms and
were diagnosed as active VL cases. Microscopic confirmation of
parasites was performed by trained technologists. The median age
of the patients was 10 years. 32% of the recruited patients were
females and 68% were males. Panels of negative sera were from 25
healthy endemic controls (EC) from the VL endemic region of
Gedaref and 20 healthy non-endemic controls (NEC) from
Khartoum, Sudan. Sera from patients with other infections
included malaria- (n=10), tuberculosis- (n=10) and Salmonella-
confirmed patients (n=10) from Khartoum, Sudan (courtesy of
Dr. Sayda El-Safi, Faculty of Medical Laboratory Sciences,
Khartoum University, Sudan). Sera samples used in this study
were collected as a part of routine diagnosis and treatment of
patients in Gedaref and Khartoum, Sudan. Patients received
standard treatment for the different disease indications as outlined
by the Federal Ministry of Health-Sudan. All samples were subject
to appropriate ethical clearance from the Faculty of Medicine,
University of Khartoum and from the National Ethical Review
Board at the Federal Ministry of Health-Sudan. The entire
Sudanese negative-sera panel had no past history of visceral
leishmaniasis. IRB approval was not sought for this study as
banked sera from IRB approved protocols were used for both the
ELISA and RDT testing. No personal identifiers were used nor
any clinical investigation carried out as part of this study.
Information about the patient’s clinical diagnosis was available
to us at the time this study was undertaken. Thirty normal human
sera (NHS) from U.S residents with no history of international
travel were used for testing non-specific reactivity of the
recombinant proteins (Equitech-Bio, Kerrville, TX).
Antibody ELISA
rK39, rK28, rK26, rK9 were titrated (200–25 gg/well) with
different dilutions of positive and negative sera (1:100, 1:200,
1:400) using a checker board titration on flat-bottomed Medi-
Sorp
TM and PolySorp
TM Nunc MicroWell
TM plates to determine
the optimized ELISA conditions. A human immunoglobulin (IgG)
standard curve was constructed using chrompure human IgG
(Jackson ImmunoResearch, West Grove, PA) and used as a
reference standard on every plate [14]. The first two columns on
every plate were coated in duplicate with 4-fold dilutions of the
standard curve (100, 25, 6.25, 1.563, 0.391, 0.098, 0.024, 0 mg/
well) in 0.1 M bicarbonate buffer pH 9.6, 0.01% BSA, 0.1%
sodium azide. The rest of the plate was coated with 25 gg /well of
the antigen in 0.1M bicarbonate buffer pH 9.6 at room
temperature for 2 hours. The non-specific reactivity on the plate
was blocked with 1% BSA in phosphate-buffered saline pH 7.2,
0.1% Tween 20 for a period of 2 hours at room temperature. The
plates were washed in wash buffer (PBS, 0.1% Tween 20) four
times and 100 ml of 1:400 dilution of the sera in serum diluent
(0.1% BSA in phosphate buffered saline pH 7.2, 0.1% Tween 20)
added to the antigen wells and 100 ml of serum diluent added to
the standard curve wells in duplicates and incubated at room
temperature for an hour on a micro plate shaker at 500 rpm. The
plates were washed in wash buffer and the bound antibodies were
assayed using 100 ml per well of 1:10,000 diluted Rec. Protein-G
HRP (Zymed, San Francisco, CA) at room temperature for
1 hour. The enzyme reaction was developed with 100 ml per well
of SureBlue TMB 1-component microwell peroxidase substrate
(KPL, Gaithersburg, MD) for 5 minutes. The reaction was
stopped using 50 ml/well of 1 M sulfuric acid, plates were read
at 450 nm on a ThermoMax microplate reader and data analyzed
using SoftMax Pro (Molecular Devices, Sunnyvale, CA). The final
conditions that produced the best observed test results for the
Sudanese panel of sera were 25 gg/well of antigen, 1:400 dilution
of serum, and a 1:10,000 dilution of recombinant protein G-HRP
as the enzyme conjugate for detection on Medisorp plate surface.
Extensive optimization experiments were performed with different
parameters in order to determine the final conditions that could
best differentiate between strong positive and borderline positive
VL sera from truly negative sera. Reproducibility of the ELISA
results were confirmed by having at least two independent
operators (blinded to the identity of test samples) perform the
same assay.
Calculations and statistical analyses
The human IgG standard curve was used as a reference
standard to control for inter-plate variation, as well as to determine
that the test was run properly. The standard curve was plotted on
a 4-parameter curve fit, and an r
2 value of 0.995 was required to
validate the data from the plate. A receiver-operator characteristic
(ROC) curve was used to evaluate all possible combinations of
sensitivity and specificity and to determine an optimal cut-off that
clearly discriminates between disease-positive and -negative sera
[15,16]. The ELISA test results from 105 non-VL sera {endemic
controls (EC), non-endemic controls (NEC), US normal human
sera (NHS) and other infection sera} were used as the negative
data set, and the results from 62 VL-confirmed sera were used as
positive data set. GraphPad Prism 4.0 software (GraphPad Prism
Inc., San Diego, CA) was used to perform the statistical analyses.
ROC curves were plotted using the software, and a table of
sensitivity and specificity with all possible cut-offs were generated
with 95% confidence intervals. The sensitivity of the test was
determined as the fraction of the VL confirmed sera that were test
positive, and specificity was calculated as the fraction of the EC,
NEC, NHS and other infection patient sera that were identified to
be truly test negative. The positive and negative predictive values
of the tests were calculated. Area under the curve (AUC) was used
as measure of diagnostic accuracy of the test providing a means to
truly discriminate between disease-positive and disease-negative
Rapid Test for Diagnosis of Visceral Leishmaniasis
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individual component antigens and rK28. A nonparametric
Spearman correlation was used to calculate the correlation
coefficient.
Development of rK28 rapid test formats (K28-LF and K28-
DPP)
Purified rK28 was provided to two manufacturers, EASE-
Medtrend (Shanghai, China) and Chembio Diagnostic Systems
(Medford, NY) to develop rapid tests. The EASE-Medtrend single
lateral flow test utilizes a proprietary dynamic flow principle. The
test antigen is immobilized on a nitrocellulose membrane within
the test zone. The liquid conjugate is applied to the device through
the reagent port, priming the device to facilitate the migration of
serum applied in the sample port. The specific antibodies present
in the serum are captured by the immobilized antigens and
subsequently visualized in the form of a magenta-colored test line
by the conjugate. In the control zone, a conjugate-binding reagent
is immobilized on the membrane. A magenta line in the control
zone appears in every valid test. The EASE-Medtrend rK28 based
prototype will be referred to as K28-LF. A subset of Sudanese VL
sera with low ELISA reactivity to rK39 were selected for studying
the additive effect of antigens on the lateral flow format using the
K28-LF RDT.
The Chembio immunoassay format is called the Dual Path
Platform (DPP). It differs from conventional lateral-flow systems in
that the test sample and the marker-detecting conjugate are
delivered to the test line area independent of each other. The DPP
assay has two laminated strips, connected to each other as a ‘‘T’’
shape inside a disposable plastic cassette. The first strip receives a
sample and running buffer through the sample port. The sample
migrates along the strip towards the second strip containing the
test and control bands. Development of the assay is achieved by
adding buffer to the development port. This step releases the
conjugate (colloidal gold) and facilitates its migration to the test
area. Antibodies, if present in the test sample, will bind to the
capture reagent immobilized on the second strip, and the
conjugate will react with this complex, making the test band
detectable by visual evaluation. Irrespective of the presence of
antibodies in the test sample, the control band should develop to
assure correct DPP assay performance. The Chembio rK28-based
prototype will be referred to as K28-DPP.
Evaluation of rK28 RDT in Sudan and Bangladesh
Testing of the two K28 RDT prototypes with larger sera panels
were carried out in parallel in Sudan and Bangladesh. The rK28-
DPP RDTs were tested in Sudan using 73 parasitology (LN
aspirates) confirmed VL samples, 24 healthy endemic controls, 18
tuberculosis- and 20 malaria- confirmed sera. Evaluation in
Bangladesh was carried out using the rK28-LF RDT and included
53 parasitologically (spleen aspirates) confirmed VL samples, 20
healthy endemic controls and 20 healthy non endemic controls.
The rK39-based Kalazar Detect (InBios International Inc. Seattle,
WA) RDT was used as a comparator in all studies.
Both rapid test formats use recombinant protein A-colloidal
gold conjugate for detection and were performed according to
manufacturer’s specifications. The test results were determined in
10 minutes for the Inbios and Ease Medtrend strips and in 15–
20 minutes for the Chembio DPP tests. Every sample was tested
twice and the results were scored by the operator as well as
independently by an individual blinded to the identity of serum
samples. While microscopic confirmation of parasites is performed
by well trained technologists, minimal training was required for
individuals scoring the RDTs.
Ethics statement
Sera samples used in this study were collected as a part of
routine diagnosis and treatment of VL patients in Gedaref
Hospital, Sudan and at the Rajshahi Medical College Hospital,
Bangladesh. Study protocols for the collection were approved by
the Institutional Review Boards of Khartoum University and
Rajshahi Medical College. In Bangladesh and Sudan, written
consent was obtained from all adult patients and parents or
guardians of children. For samples from illiterate adult participants
and children, verbal consent was read to and discussed with
adults/guardians in presence of a literate relative, the consent form
was signed by the literate relative and a fingerprint was obtained
from the parent/guardian. IRB approval was not sought for this
study as banked sera from IRB approved protocols were used
for both the ELISA and RDT testing (retrospective study). No
personal identifiers were used nor any clinical investigation
carried out as part of this study. Information about the patient’s
clinical diagnosis was available to us at the time this study was
undertaken.
Results
Design of the k28 synthetic gene and expression of
recombinant K28 protein
The synthetic gene k28 was designed by fusing nucleotide
sequences for three 14-aa tandem repeats of the L. donovani haspb1
gene [17], two 39-aa tandem repeats of the L. donovani kinesin gene
[18] and the entire 133 aa of the L. donovani haspb2 gene
(Figure 1A) [17]. The 795 bp nucleotide sequence cloned in pET-
29a was used to express an N-terminal 6XHis-tagged recombinant
protein in E. coli. The fusion protein was purified by affinity
chromatography over a Ni-NTA agarose matrix. The 264-aa
sequence (Figure 1B) encoded an acidic protein (pI 4.73) with a
predicted molecular weight of 28.33 kDa. The protein migrated
aberrantly around 40 kDa on SDS-PAGE (Figure 1C). Hypothet-
ically, the mobility of rK39 and rK28 should be slower than the
mobility of rK26. The predicted molecular masses of both rK39
(35.3 kDa) and rK28 (28.33 kDa) are indeed higher than that of
rK26 (26 kDa) and yet they seem to migrate faster compared to
rK26 (26 kDa). The slower mobility of rK26 is due to its higher
proline content compared to either rK28 or rK39.This charac-
teristic has been observed for other proteins with high acidity and
high proline/lysine content including HASPB1, K26 and K9
[11,17,19].
ELISA test results with Sudanese sera on rK28, rK39, rK26,
and rK9
In order to evaluate the antigen-specific antibody responses
against rK28, rK39, rK26, and rK9, antibody ELISA’s were
optimized to obtain the best signal-to-noise ratio and develop a
reproducible and robust assay that was capable of capturing
antibodies over a biologically relevant assay range. Sudanese
parasitology confirmed VL-positive and -negative sera (NHS, EC,
NEC and other infection sera) were tested by ELISA on rK28,
rK39, rK26, and rK9 to evaluate immunoreactivities (expressed as
A450nm in Fig. 2) against individual proteins. The overall OD
responses of individual VL-confirmed sera were quite similar for
rK39 and rK28 antigens (Fig. 2A and B, respectively), and both
were much higher than the responses to rK26 and rK9. The
ELISA cut-off values of the 4 recombinant proteins rK28, rK39,
rK26, and rK9 were 0.4151, 0.3043, 0.3149, and 0.1589,
respectively, and were determined by ROC (Receiver-Operator
Curve) analyses of the absorbance values at 450 nm (Table 1).
Rapid Test for Diagnosis of Visceral Leishmaniasis
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The sensitivity, specificity and area under the curve (AUC) were
calculated for all 4 recombinant proteins (Table 1). rK28 was test-
positive on 60 of the 62 VL-positive serum samples, yielding a
sensitivity of 96.8%, while rK39 had a sensitivity of 93.5% (58/62).
rK26 and rK9 both missed 6 out of 62 VL positive sera and had
sensitivities of 90.3%. Specificity was calculated using a panel of
105 sera that included healthy endemic, healthy non-endemic, and
other confirmed infectious disease sera, together with sera from
healthy non-travelers from the United States. Based on the ELISA
cut-off (Table 1), rK26 had the highest specificity of 97.1%, closely
followed by rK28 with a specificity of 96.2%. rK39 had a
specificity of 92.4% while the least specific was rK9 with a
specificity of 82.9%. All healthy U.S donors (30 samples) were test-
negative on rK39, rK28 and rK26 ELISA. rK9 was least specific,
as 4/30 U.S donors reacted non-specifically on the ELISA (data
not shown). The area under the curve (AUC) is a widely accepted
metric for evaluating diagnostic accuracy [20]. The greater the
AUC, the better the accuracy of the diagnostic test, and an AUC
of 1 represents perfect accuracy [21]. The ROC curves obtained
for the ELISA using absorbance values for rK28, rK39, rK26 and
rK9 are shown in Figure 3. rK28 had the highest AUC (AUCrK28)
with a value of 0.98. This was followed in order of accuracy by
AUCrK26=0.97, AUCrK39=0.96, and finally AUCrK9=0.94.
Benefits of the cumulative effect of rK28 in low reactive
K39 VL serum
rK28 is a fusion polyprotein comprising regions of L. donovani
haspb1 (L. infantum k26 homologue), L. donovani kinesin (L. infantum
k39 homologue) and L. donovani haspb2 (L. infantum k9 homologue).
For many of the Sudanese VL sera tested, the relative absorbance
observed were higher on the rK28 ELISA compared to rK39,
rK26 or rK9. We also observed a subset of individual sera with
very low reactivity to rK39, but much higher reactivity to rK28.
Figure 1. Design of the k28 gene. A: The complete amino acid sequence of the k28 gene contains an amino terminal 6 histidine tag followed by
three 14 amino acid tandem repeat regions of the haspb1 gene (shown in blue), two 39 amino acid tandem repeat regions of the L. donovani k39
kinesin gene (shown in red) and 133 amino acid full length open reading frame of the haspb2 gene (shown in green). B: Schematic showing the rK28
fusion protein. C: 2.5 mg of purified rK9, rK26, rK28, rK39 run on a 4–22% polyacrylamide gradient gel under reducing conditions and stained with
simplyblue safestain.
doi:10.1371/journal.pntd.0000822.g001
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plotted against the absorbance values of the three individual
proteins rK39, rK26 and rK9 and are shown as scatter plots
(Figure 4). A nonparametric spearman correlation analysis was
done to calculate the correlation coefficient r and two-tailed P
values. The antibody levels measured by rK39 and rK28
Figure 2. Comparison of ELISA reactivity of Sudanese sera against rK39, rK28, rK26 and rK9 proteins. Antigen specific antibody titers of
individual Sudanese human sera grouped based on their clinical status. Results are expressed as the optical densities at 450 nm (A450). The antigens
were coated at 0.25 mg/ml. A: rK39, B: rK28, C: rK26, D: rK9. The cut off values chosen from the ROC curves are shown as lines and are 0.304, 0.415,
0.315, and 0.159 for rK39, rK28, rK26 and rK9 ELISA respectively.
doi:10.1371/journal.pntd.0000822.g002
Table 1. ELISA (A450) results and diagnostic accuracy of testing Sudanese human sera on recombinant proteins.
Antigen Cutoff (A450) Sensitivity* 95% Confidence Interval Specificity* 95% Confidence Interval Area Under the Curve
rK39 0.3043 0.9355 84.30–98.21% 0.9238 85.54–96.65% 0.9565
rK28 0.4151 0.9677 88.83–99.61% 0.9619 90.53–98.95% 0.9839
rK26 0.3149 0.9032 80.12– 96.37% 0.9714 91.88–99.41% 0.9708
rK9 0.1589 0.9032 80.12–96.37% 0.8286 74.27–89.51% 0.9424
*Sensitivity measures the fraction of actual disease positives that are correctly identified by the test. Specificity measures the fraction of disease negatives that are
correctly identified by the test.
doi:10.1371/journal.pntd.0000822.t001
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r=0.7141, P,0.0001); rK9 and rK28 (Spearman r=0.4112,
p=0.0009) displayed a positive and significant correlation.
Overall, there seemed to be a cumulative increase in the absolute
magnitude of the antibody responses when using rK28 protein to
capture serum antibodies. In order to investigate the cumulative
effects of rK28, VL sera with low K39 reactivity were selected, and
the responses against individual proteins titrated against 10-fold
serial dilutions of the sera (1:100–1:1000000) in an ELISA
(Figure 5). We observed that a majority of the VL sera tested in
this manner had a much higher response to rK28 and in some
cases a stronger response to rK26 (Figure 5C).This may be due to
the fact that rK28 can capture circulating antibodies against all
three component proteins (Haspb1, LdK39, and Haspb2) leading
to a more robust signal. Therefore, it is likely that tests using rK28
protein could potentially diagnose individuals that are missed by
rK39.
Development of K28-LF RDT and prototype testing in
Bangladesh
In order to evaluate rK28 on a point-of-care test, single lateral
flow RDT prototypes (K28-LF) were developed by EASE
MedTrend (Shanghai, PRC) based on their proprietary dynamic
flow principle. Preliminary screening of 13 VL Sudanese sera
(selected on the basis of low rK39 ELISA reactivity) demonstrated
a much higher sensitivity for the K28-LF (92.3%) compared to a
much lower sensitivity with Kalazar Detect (69.2%) (Table 2).
Neither RDTs gave any false positive results with sera from U.S
healthy subjects. To obtain a more realistic performance of the
RDTs in a VL endemic region, we next evaluated both the rK28-
LF and Kalazar Detect on a larger panel of VL confirmed sera in
Bangladesh. 53 parasitology confirmed VL sera and 40 healthy
endemic control sera with no history of VL were evaluated. Once
again the K28-LF RDT provided more favorable results (98.1%
sensitivity, 92.5% specificity) compared to Kalazar Detect (88.7%
sensitivity, 100% specificity) (Table 3).
Development of rK28-DPP RDT and prototype testing in
Sudan
A second prototype test of rK28 (K28-DPP) using a distinct
technology was developed by Chembio Diagnostic systems. Sera
from 73 parasitology confirmed VL patients who were DAT or
smear-positive and 62 negative sera (24 endemic controls, 20
malaria- and 18 tuberculosis-confirmed patients) with no history of
VL were evaluated in Sudan. All sera were also tested with
Kalazar Detect as a comparator (Table 4). The K28-DPP RDT
Figure 3. ROC curves generated from the ELISA values of Sudanese sera against rK39, rK28, rK26, and rK9. The curves were used to
determine ELISA cutoff, sensitivity and specificity. A: rK39, B: rK28, C: rK26, D: rK9.
doi:10.1371/journal.pntd.0000822.g003
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specificity of 100% while the Kalazar Detect yielded a sensitivity of
86.3% and specificity of 96.4%. The DAT, which was performed
on every serum sample used in this study, provided a sensitivity of
94.5% and specificity of 100%.
Discussion
Aspirates from bone marrow, lymph nodes or the spleen are
typically done to confirm the diagnosis of visceral leishmaniasis.
Although the specificity is high, the sensitivity of microscopy
varies and is greatly influenced by the experience of the individual
making the smear, the quality of the smear, and the reagents
used. Microscopy is available only in tertiary care or referral
centers/hospitals in endemic countries and is a time-consuming
procedure. These factors make it difficult to accurately diagnose
VL patients in primary care settings. The identification of rK39 as
a marker of active VL disease [5] followed by its use in a rapid test
format [9] has revolutionized VL diagnosis in the Indian
subcontinent. While the rK39-based rapid test has greater than
95–98% sensitivity in the Indian subcontinent and is now widely
used as a means of confirming diagnosis of VL patients, its
sensitivity is lower in the VL endemic regions of Africa, limiting its
usefulness as a widely used point-of-care serodiagnostic test.
Detailed studies of human leukocyte antigen (HLA) polymor-
phisms between VL subjects from the Indian and African
subcontinents would be valuable to explain differences in epitope
specificities between these populations.
This study was initiated with the goal of developing a highly
sensitive, specific, cost-effective, and rapid point-of-care serodiag-
nostic test for VL diagnosis that would improve upon the rK39
RDT. Our strategy included design of a synthetic gene, k28,
harboring sequences fused from three L. donovani tandem repeat
containing genes (haspb1, LdK39 and haspb2). Previous work done
Figure 4. Correlations in serum responses between rK28 and the individual component proteins rK39, rK26 and rK9 on testing with
Sudanese VL patient sera. Correlation coefficients were calculated using ELISA results of sera from 62 individuals with confirmed VL. A:
Comparison of antibody levels (OD) against rK28 and rK39, B: Comparison of antibody levels (OD) against rK28 and rK26, C: Comparison of antibody
levels (OD) against rK28 and rK9. Sudanese VL patients with extremely low rK39 antibody titers demonstrate much higher titers against rK28 as
demonstrated by a strong and statistically significant positive correlation on the Spearman test (r=0.8383, p,.0001).
doi:10.1371/journal.pntd.0000822.g004
Figure 5. Serum titrations of low rK39 reactive VL-confirmed patient sera evaluated on ELISA. A450 values show a cumulative increase in
serum responses to rK28 polyprotein compared to proteins rK39, rK26 and rK9. A: VL-confirmed sera from patient 1; B: VL-confirmed sera from patient
2; C: VL-confirmed sera from patient 3.
doi:10.1371/journal.pntd.0000822.g005
Rapid Test for Diagnosis of Visceral Leishmaniasis
www.plosntds.org 8 September 2010 | Volume 4 | Issue 9 | e822by our group revealed that increasing the number of tandem
repeat units exponentially increases the ability to capture
antibodies in the serum [22]. We utilized this information and
incorporated multiple tandem repeat regions of haspb1 and LdK39
in order to increase the antigen epitope density within the resulting
fusion protein. The L. infantum homologues of these genes have
previously been shown to have good serodiagnostic value for both
human and canine VL [11,12,13]. The tandem repeat regions
found in many protozoan proteins usually contain immunodomi-
nant B-cell epitopes capable of generating high levels of antibody
response in infected individuals [23,24,25,26].
Serological responses of Sudanese VL patients were tested by
ELISA against rK28 and compared with individual L. infantum
homologue proteins rK39, rK26, and rK9. In order to model a
realistic scenario in a VL endemic country, our specificity data
included healthy endemic and non-endemic control sera as well as
sera from individuals with other diseases. Healthy human sera
from the USA were also included as part of the specificity panel to
evaluate if the recombinant proteins had any false positive
reactivities. From the testing done on ELISA, rK28 was more
sensitive and specific than rK39. The ROC curves also predicted a
higher diagnostic accuracy for rK28 compared to rK39.
We next sought to determine whether VL sera with low/
borderline ELISA reactivity against rK39 could be detected with
greater accuracy using rK28. Our results showed that many of the
rK39 low-reactive sera had higher reactivity to rK28 and in some
instances to rK26. The benefit of using rK28 for VL diagnosis
arises from its ability to capture circulating antibodies to 3
Leishmania antigens compared to rK39, which binds antibodies
specific to a single antigen. The cumulative antibody binding
observed with rK28 raises the intensity of the signal and makes the
border-line positive low rK39 sera distinctly positive.
The higher sensitivity of rK28 in effectively identifying low rK39
sera prompted us to exploit this characteristic for developing rK28-
based point-of-care rapid tests. rK28 was provided to two inde-
pendent manufacturers for prototype RDT development to ensure
that test format-specific constraints would not limit product develop-
ment.Also,having multiplemanufacturerscreatesa healthycompeti-
tion promoting lower costs and better quality tests for clinicians.
Testing of 13 low rK39 reactive Sudanese VL sera with the
rK28-LF prototype confirmed significantly higher sensitivity (92%)
afforded by a rK28-based test in comparison to the Kalazar Detect
test (69%). To evaluate accuracy of the rK28 RDT prototypes in
detecting VL patients, independent studies were conducted with
larger sera samples in Sudan and Bangladesh, two countries where
VL is endemic. As the prototype tests were manufactured on a
small scale for conducting pilot studies, the two RDT prototypes
could not be tested in both countries. The rK28-DPP afforded
96% sensitivity in detecting DAT or smear-positive active VL
patients in Sudan, while the rK28-LF RDT provided 98%
sensitivity in detecting microscopy-confirmed active VL cases in
Bangladesh. Overall, both rK28-based prototype tests proved
more sensitive in detecting VL cases compared to the rK39-based
tests. rK28-DPP tests also proved to be highly specific (100%) in
Sudan while the rK28-LF was somewhat less specific (92.5%) in
Bangladesh. Large-scale field studies in both countries for selection
of the final test format are planned. Further testing in the field and
close follow-up of healthy individuals in VL endemic areas who
have tested positive on the rK28 tests, but lack clinical symptoms,
will further illustrate characteristics of the fusion protein and help
us determine whether rK28 is capable of acting as an early marker
of infection. The samples used as a part of this study were VL
patients confirmed by parasitology, therefore, the role of K28
rapid test in detecting parasitology negative and DAT negative VL
patients is yet to be studied. This will be crucial in determining the
true accuracy of the rapid tests.
Due to the lack of accurate and non-invasive field-applicable
tests, VL patients (a majority of whom are children) undergo
extreme pain and discomfort as a result of diagnosis by tissue
biopsy. The K28 RDT’s could become a crucial tool for VL
diagnosis, providing an easy alternative to biopsies. Early diagnosis
and treatment of VL are crucial for both the affected individual
and for the community. Untreated VL patients act as a reservoir of
disease, especially in Africa and the Indian subcontinent where the
disease is anthroponotic. Early and accurate case detection and
treatment are essential components in VL control and elimination
programs. Identification of affected individuals using an affordable
serodiagnostic test prior to using expensive confirmatory tests for
Table 2. Results of weak rK39-reactive Sudanese VL sera on K28-LF and Kalazar Detect RDTs.
Sudan Sera % Sensitivity 95% Confidence Interval % Specificity 95% Confidence Interval
K28-LF* 92.3 63.97–99.81% 100 88.43–100.0%
Kalazar Detect* 69.2 38.57–90.91% 100 88.43–100.0%
No. of Sera Tested 13 30
*K28-LF is manufactured by Ease-Medtrend, and the Kalazar Detect is manufactured by Inbios International, Inc. A panel of US healthy sera was used for specificity
testing.
doi:10.1371/journal.pntd.0000822.t002
Table 3. Results of testing human VL sera from Bangladesh on K28-LF and Kalazar Detect RDTs.
Bangladesh Sera % Sensitivity 95% Confidence Interval % Specificity 95% Confidence Interval
K28-LF* 98.1 89.93–99.95% 92.5 79.61–98.43%
Kalazar Detect* 88.7 76.97–95.73% 100 91.19–100.0%
No. of Sera Tested 53 40
*K28-LF is manufactured by Ease-Medtrend and the Kalazar Detect test is manufactured by Inbios International, Inc. All VL patient sera were confirmed by splenic
aspirates. Sera from healthy endemic individuals were used as controls for specificity testing.
doi:10.1371/journal.pntd.0000822.t003
Rapid Test for Diagnosis of Visceral Leishmaniasis
www.plosntds.org 9 September 2010 | Volume 4 | Issue 9 | e822parasite detection and subsequent initiation of treatment would
greatly impact timely case management and disease control. Use
of a low-risk, field-based diagnostic test to detect active disease
with greater accuracy, as well as monitor sub-clinical infection
rates would significantly impact population-based control of
disease and potentially reduce time to cure for individual patients.
Multicenter large scale field evaluation of these prototype formats,
including the rK39-based RDT as a comparator, are being
planned to enable selection of a rK28-based RDT.
In conclusion, we have designed a new synthetic fusion protein
for improved serodiagnosis of VL. The rK28 protein affords
higher sensitivity in detecting active VL cases compared to rK39
both on ELISA and RDT format. The development of an rK28-
based point-of-care test has yielded promising results and will
become a valuable tool in rapid diagnosis of VL in conjunction
with complementary tools such as parasite circulating antigen
detection tests and nucleic acid detection tests and permit
addressing the under-reporting of this neglected disease.
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